Results 101 to 110 of about 1,266 (177)

The 24 hour lung function time profile of olodaterol once daily versus placebo and tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease

, 2014
Background: Olodaterol is a once-daily long-acting β2-agonist being investigated for the treatment of chronic obstructive pulmonary disease, with ≥ 24 hour bronchodilator activity.
Aumann, Joseph-Leon, Hamilton, Alan, Lange, Peter, Tetzlaff, Kay, Ting, Naitee, Derom, Eric   +5 more
core   +1 more source

Tioropium+Olodaterol Respimat; Budget Impact In The Uk [PDF]

Value in Health, 2015
Ternouth, A, Tebboth, A, Selya-Hammer, C, Gonzalez-Rojas Guix, N   +3 more
openaire   +2 more sources

Effect of tiotropium/olodaterol on sedentary and active time in patients with COPD: post hoc analysis of the VESUTO® study

International Journal of COPD, 2019
Yoshiaki Minakata,1 Takashi Motegi,2 Jun Ueki,3 Yasuhiro Gon,4 Shuhei Nakamura,5 Tatsuhiko Anzai,6 Kazuto Hirata,7 Masakazu Ichinose81Department of Respiratory Medicine, National Hospital Organization Wakayama Hospital, Wakayama, Japan; 2Department of ...
Minakata Y, Motegi T, Ueki J, Gon Y, Nakamura S, Anzai T, Hirata K, Ichinose M   +7 more
doaj  

Olodaterol in model systems of fibrosis

, 2017
published
openaire   +1 more source

New drugs: Olodaterol [PDF]

Australian Prescriber, 2014
openaire   +1 more source

Safety analysis of long-acting dual bronchodilator after market approval: a real-world study from FDA Adverse Event Reporting System (FAERS) database. [PDF]

J Thorac Dis
Gao S, Zhuang W, Song Q, Yan D, Chen L, Lai Z, Cheng Y, Yang X, Hu S.   +8 more
europepmc   +1 more source

Tiotropium Bromide/Olodaterol Related Acute Cognitive Impairments

Case Reports in Clinical Medicine, 2023
Samer Alkhuja, Monika Girgis
openaire   +1 more source

Cardiac disorders associated with compound long-acting bronchodilators for inhalation: a pharmacovigilance analysis of the FDA adverse event reporting system database. [PDF]

Front Cardiovasc Med
Lan Y, Hu D, Huang S, Xu M, He Q.
europepmc   +1 more source

Evaluating Arrhythmia Risk in Patients with Chronic Obstructive Pulmonary Disease Treated with Aclidinium/Formoterol Fumarate and Other Inhaled Bronchodilators: A Post-Authorization Safety Study. [PDF]

Int J Chron Obstruct Pulmon Dis
Rebordosa C, Aguado J, Bartsch J, Saigi-Morgui N, Carsin AE, Garcia-Esteban R, Ignatova E, Freedman D, Perez-Gutthann S, Rivero-Ferrer E.   +9 more
europepmc   +1 more source

Drug-related pulmonary fibrosis: A real-world pharmacovigilance study of the FDA Adverse Event Reporting System. [PDF]

Medicine (Baltimore)
Jian R, Yang L, Guo J, Shi E, Du M, Jin H, Zhen H.   +6 more
europepmc   +1 more source